Loading…
VYGR
Voyager Therapeutics, Inc.
NASDAQ· Healthcare· Biotechnology
$3.54+2.31%
Key metrics
- Market cap
- $218.13M
- P/E
- —
- Forward P/E
- —
- P/B
- 1.2x
- Dividend yield
- —
- EPS
- -$1.81
- ROE
- -54.09%
- Profit margin
- 0.00%
- Revenue growth
- -39.10%
- Beta
- 1.31
- 52-week high
- $5.55
- 52-week low
- $2.94
History
How the company evolved, year by year. Revenue and debt come from the annual statements; dividends from the payments themselves, which reach further back.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Investors holding this
Major managers that reported this stock in their latest 13F.
About the company
Voyager Therapeutics, Inc., a biotechnology company, focuses on the human genetics for the cure of neurological diseases. Its product pipeline includes VY1706, a tau silencing gene therapy and VY7523, an anti-tau antibody program for the treatment of alzheimer's disease. The company also provides research program for the treatment of Huntington's disease. In addition, it offers TRACER, an adeno-associated virus (AAV) capsid discovery platform; ALPL-VYGR-NeuroShuttle, to target an undisclosed neurological disease; and develops selective small molecules for the treatment of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia with TDP-43 pathology. The company has collaboration and license agreements with Alexion; AstraZeneca Ireland Limited; Novartis Pharma AG; and Transition Bio, Inc. for the treatment of various other diseases of the central nervous system. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.
- 141
- Lexington, United States
Company description provided by Yahoo Finance.